The Question of Investment in Antimicrobials

Back Bay Life Science Report

Contenido proporcionado por Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

3+ y ago 25:25

MP3•Episodio en casa

In this episode Jonathan Gertler, Back Bay’s CEO and Managing Partner, sits down with Dr. Peter Bak, Managing Director at Back Bay, to discuss Dr. Bak’s latest article in STAT News and to talk about the world of anti-infectives.

Dr. Bak has more than ten years of expertise in infection and treatment. He began his research at Dartmouth Medical School and later continued at MIT, where he was an American Cancer Society Postdoctoral Fellow at the Koch Institute of Integrative Cancer Research.

Topics include:

-The landscape of antiinfectives, antimicrobials & antifungals -How commercial dynamics drive clinical unmet need -The role the pandemic played on development & investments -The deployment of cell therapies for viral diseases -Foundation support for anti-infectives -“Push incentives” to usher therapies into commercial stages

Link to Dr. Peter Bak's published article in STAT News, “Investment in antimicrobials was up in 2020, but much work remains," https://www.statnews.com/2021/04/28/investment-antimicrobials-uptick-2020-much-work-remains/

28 episodios

#Fitness #Medicine #Bay Life Science Advisors #Jonathan P. Gertler #Biopharma #Investmentbanking #LifeSciences #Medtech